NLA- SAP Module 1- The Science of Lipidology: Lipid Metabolism, Pathogenesis of Atherosclerosis and Genetic Disorders V2
Cardiology
Credits:
12 AMA PRA Category 1 Credit(s) ™ 11.8 ANCC Contact Hours 12 ACPE 12 CDR
12 AMA PRA Category 1 Credit(s) ™ 11.8 ANCC Contact Hours 12 ACPE 12 CDR
Launch Date:
November 15, 2016
November 15, 2016
Expiration Date:
The accreditation for this activity has expired.
The accreditation for this activity has expired.
Primary Audience:
Lipidologists, Lipid Specialists, Cardiologists, Endocrinologists, Internists, Nephrologists, Primary Care Physicians, Family Practitioners, PhDs, Physicians Assistants, Cardiovascular Nurses, Nurse Practitioners, Pharmacists, Dietitians
Relevant Terms:
Atherosclerosis, Genetic Disorders
See Faculty section below for a complete list of faculty.
See Faculty section below for a complete list of faculty.
Bio| 1. | Describe the pathophysiology of lipoprotein metabolism. | 2. | Review the biochemical basis of abnormal lipid metabolism, noting areas that are targeted in both current and potential future therapies. |
| 3. | Describe genetic disorders affecting lipoprotein metabolism and their molecular etiology. | 4. | Review the underlying genetic mutations of various hereditary dyslipidemias. |
| 5. | Review the pathogenesis of atherosclerotic plaque development and progression, including the role of inflammation. | 6. | Review representative clinical cases in the management of patients with dyslipidemia. |
| 7. | Identify primary and secondary causes of dyslipidemia and their mechanisms in dyslipidemic disease expression |
| 1. | Describe the pathophysiology of lipoprotein metabolism. |
| 2. | Review the biochemical basis of abnormal lipid metabolism, noting areas that are targeted in both current and potential future therapies. |
| 3. | Describe genetic disorders affecting lipoprotein metabolism and their molecular etiology. |
| 4. | Review the underlying genetic mutations of various hereditary dyslipidemias. |
| 5. | Review the pathogenesis of atherosclerotic plaque development and progression, including the role of inflammation. |
| 6. | Review representative clinical cases in the management of patients with dyslipidemia. |
| 7. | Identify primary and secondary causes of dyslipidemia and their mechanisms in dyslipidemic disease expression |
CRITERIA FOR SUCCESS
In order to receive credit for this enduring program, participants must answer each question, review the ensuing critiques and evaluate the activity. A statement of credit will be available upon completion of an evaluation form. If you have questions about this CME/ CE activity, please contact the NLA at cme@lipid.org.
For Pharmacists: Upon receipt of the completed activity evaluation form, transcript information will be available at www.mycpemonitor.net within 4 weeks.
Physicians who complete a program evaluation will receive a Statement of Continuing Education Credit from the NLA for up to 12 hours of AMA PRA Category 1 Credits™ toward the AMA Physician Recognition Award. To receive credit you must obtain a 30% or greater total score on your Performance Score Report.
COMMERCIAL SUPPORT
There is no commercial support for this activity.
CREDIT DESIGNATION
CME credit provided by the National Lipid Association The National Lipid Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The National Lipid Association designates this enduring activity for a maximum of 12 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in this activity.
Physician Assistants
NCCPA accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.
Dietitians
The National Lipid Association is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). Registered dietitians (RDs) and dietetic technicians, registered (DTRs) will receive 12 continuing professional education units (CPEUs) for completion of this program/ materials. CDR Accredited Provider #NL002.
The National Lipid Association designates this enduring activity for a maximum of 12 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in this activity.
Physician Assistants
NCCPA accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.
Dietitians
The National Lipid Association is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). Registered dietitians (RDs) and dietetic technicians, registered (DTRs) will receive 12 continuing professional education units (CPEUs) for completion of this program/ materials. CDR Accredited Provider #NL002.
CE Credit provided by Postgraduate Institute for Medicine Pharmacists
Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Universal Activity Number 0809-9999-16-454-H01-P (Knowledge)
Postgraduate Institute for Medicine designates this continuing education activity for 12 contact hour(s) (1.2 CEUs) of the Accreditation Council for Pharmacy Education
Nursing
This educational activity for 11.8 contact hours is provided by the Postgraduate Institute for Medicine.
Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
Postgraduate Institute for Medicine designates this continuing education activity for 12 contact hour(s) (1.2 CEUs) of the Accreditation Council for Pharmacy Education
Nursing
This educational activity for 11.8 contact hours is provided by the Postgraduate Institute for Medicine.
Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
This self-assessment program is recognized for Maintenance of Certification by the American Board of Clinical Lipidology and Renewal of Certification by the Accreditation Council for Clinical Lipidology.
FACULTY
Editor-in-Chief
Carl E. Orringer, MD, FNLA*
Associate Professor of Medicine
University of Miami Miller School of Medicine
Miami, FL
Carl E. Orringer, MD, FNLA*
Associate Professor of Medicine
University of Miami Miller School of Medicine
Miami, FL
Associate Editor
Sergio Fazio, MD, PhD, FNLA*
The William and Sonja Connor
Chair of Preventive Cardiology
Professor of Medicine and Physiology & Pharmacology
Director, Center for Preventive Cardiology
Knight Cardiovascular Institute
Oregon Health and Science University
Portland, OR
Contributing Editors
Kenneth R. Feingold, MD
Professor of Medicine
University of California San Francisco
Chief, Endocrine Clinic
San Francisco VA Medical Center
San Francisco, CA
Kenneth R. Feingold, MD
Professor of Medicine
University of California San Francisco
Chief, Endocrine Clinic
San Francisco VA Medical Center
San Francisco, CA
Michael D. Shapiro, DO, FNLA*
Associate Professor of Medicine and Radiology
Director, Cardiac MR CT Program
Center for Preventive Cardiology
Knight Cardiovascular Institute
Oregon Health & Science University
Portland, OR
Associate Professor of Medicine and Radiology
Director, Cardiac MR CT Program
Center for Preventive Cardiology
Knight Cardiovascular Institute
Oregon Health & Science University
Portland, OR
*Denotes Diplomate, American Board of Clinical Lipidology.
DISCLOSURES
Sergio Fazio, MD, PhD, FNLA has served as a consultant for Aegerion Pharmaceuticals Inc, BASF Corporation, Kowa Pharmaceuticals America, Inc., Merck & Co., Inc., New Haven Pharmaceuticals, Inc., and sanofi-aventis U.S.
Kenneth R. Feingold, MD has served as a speaker for Amgen, Merck and Co., Inc., Regeneron Pharmaceuticals, and sanofi-aventis U.S..
Carl E. Orringer, MD, FNLA has nothing to disclose.
Michael D. Shapiro, DO, FNLA has served as a consultant for Alexion Pharmaceuticals and Synta.
Reviewer:
Nicole Woodsmall, MSH, RDN has nothing to disclose.
CME Reviewer:
Linda C. Hemphill, MD, FNLA has served on advisory boards for Aegerion and Regeneron Pharmaceuticals. She has also recieved research grants from Ionis, sanofi-aventis U.S., and Regeneron Pharmaceuticals.
NLA staff has nothing to disclose.
PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, RN, BSN, and Jan Schultz, RN, MSN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
DISCLOSURE OF UNLABELED USE AND INVESTIGATIONAL PRODUCT
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLOSURE DECLARATION
It is the policy of NLA to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. Planners, faculty, reviewers, and staff have disclosed any financial relationships with commercial interests as defined by the ACCME.
It is the policy of NLA to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. Planners, faculty, reviewers, and staff have disclosed any financial relationships with commercial interests as defined by the ACCME.
DISCLAIMER
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. The NLA specifically disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through reader’s misunderstanding of content.
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. The NLA specifically disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through reader’s misunderstanding of content.
COURSE VIEWING REQUIREMENTS
| Supported Browsers: Internet Explorer 9.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 Google Chrome 28.0+ for Windows, Mac OS, or Linux Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux Safari 6.0+ for Mac OSX 10.7 and above | Supported Phones & Tablets: Android 4.0.3 and above iPhone/iPad with iOS 6.1 or above. |
© 2007-2026 HealthCourse, Inc. All rights reserved.
